Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant

Rhea-AI Filing Summary

Kura Oncology, Inc. director Diane L. Parks received an option grant for 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. According to the grant terms, it vests in full on the one-year anniversary of the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Parks Diane L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	35,000	$0.00	--

Holdings After Transaction: Option to purchase common stock — 35,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 35,000 shares Exercise price: $8.77 per share Expiration date: June 3, 2036 +1 more

4 metrics

Option grant size 35,000 shares Option to purchase common stock granted to director

Exercise price $8.77 per share Conversion or exercise price of granted options

Expiration date June 3, 2036 Option expiration for director grant

Post-grant option holdings 35,000 derivative shares Total option shares following this transaction

Key Terms

Option to purchase common stock, Grant, award, or other acquisition, derivative security, vests in full

4 terms

Option to purchase common stock financial

"security_title: Option to purchase common stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative security financial

"transaction_type: derivative"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vests in full financial

"This option vests in full on the one year anniversary"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parks Diane L.

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$8.77	06/04/2026		A		35,000		(1)	06/03/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

	/s/ Teresa Bair, Attorney-in-fact for Diane Parks	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kura Oncology (KURA) director Diane L. Parks report on this Form 4?

Diane L. Parks reported receiving an option to purchase 35,000 Kura Oncology common shares. This is a compensation-related grant, not an open-market stock purchase or sale, and is reflected as a derivative security award on the Form 4.

How many Kura Oncology (KURA) stock options were granted to Diane L. Parks?

Diane L. Parks was granted options for 35,000 shares of Kura Oncology common stock. These options represent her total holdings of this option grant immediately after the transaction, with 35,000 derivative shares reported following the award.

What is the exercise price of Diane L. Parks’ Kura Oncology (KURA) options?

The option grant to Diane L. Parks has an exercise price of $8.77 per share. This means she can purchase Kura Oncology common stock at $8.77 for each of the 35,000 underlying shares if she exercises the options.

When do Diane L. Parks’ Kura Oncology (KURA) options vest?

The options granted to Diane L. Parks vest in full on the one-year anniversary of the grant date. Until that vesting date, the option award remains unvested, after which she can exercise all 35,000 underlying shares subject to plan terms.

When do Diane L. Parks’ Kura Oncology (KURA) options expire?

Diane L. Parks’ option award expires on June 3, 2036. After this expiration date, any unexercised portion of the 35,000-share option will no longer be exercisable, so the right to purchase shares ends on that day.

Is Diane L. Parks buying or selling Kura Oncology (KURA) shares in this Form 4?

This Form 4 does not show an open-market buy or sell by Diane L. Parks. It reports a grant or award acquisition of stock options, classified under transaction code “A,” rather than a purchase (“P”) or sale (“S”) of existing common shares.